LHM3 can be used in a diagnostic panel for immunopathology of malignant melanoma. Potential candidate for immunoimaging and immunotherapy of disseminated melanoma.
| Inventor | Institute |
|---|---|
| Nick Tidman | Cancer Research UK, London Research Institute: Lincoln's Inn Fields |
| SKU: | 152695 |
|---|---|
| Product description: | LHM3 can be used in a diagnostic panel for immunopathology of malignant melanoma. Potential candidate for immunoimaging and immunotherapy of disseminated melanoma. |
| Conjugation: | Unconjugated |
| Isotype: | IgG1 kappa |
| Molecular weight: | 120 kDa |
| Immunogen: | A 375P cell extract |
| Cat. #: | 152695 |
|---|---|
| Provenance and Ownership: | The Anti-Melanoma [LHM3] is owned by Cancer Research UK. CancerTools supplies the Anti-Melanoma [LHM3] under licence from Cancer Research UK and is the authorised source for its distribution. Sourcing Anti-Melanoma [LHM3] directly from the IP owner ensures authenticity, provenance and compliance with all applicable licensing and research use requirements. |
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Cancer types: | Other |
| Research Fields: | Cancer; Cell biology |
| Application: | IHC ; IF ; IP ; WB |
| Target: | Melanoma |
| Reactivity: | Human |
| Clone: | LHM3 |
| Host: | Mouse |
| Class: | Monoclonal |
| Target background: | LHM3 can be used in a diagnostic panel for immunopathology of malignant melanoma. Potential candidate for immunoimaging and immunotherapy of disseminated melanoma. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Kupsch et al. 1995. Melanoma Res. 5(6):403-11. PMID: 8589614. Generation and selection of monoclonal antibodies, single-chain Fv and antibody fusion phage specific for human melanoma-associated antigens. |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.